Literature DB >> 19818867

Acute bronchodilator responsiveness in subjects with and without airflow obstruction in five Latin American cities: the PLATINO study.

Maria Montes de Oca1, Rogelio Perez-Padilla, Carlos Tálamo, Ronald J Halbert, Dolores Moreno, Maria Victorina Lopez, Adriana Muiño, B Jardim José Roberto, Gonzalo Valdivia, Julio Pertuzé, B Menezes Ana Maria.   

Abstract

BACKGROUND: Acute bronchodilator responsiveness is an area of discussion in COPD. No information exists regarding this aspect of the disease from an unselected COPD population. We assessed acute bronchodilator responsiveness and factors influencing it in subjects with and without airway obstruction in an epidemiologic sample.
METHODS: COPD was defined by GOLD criteria (post-bronchodilator FEV(1)/FVC<0.70). In this analysis, subjects with pre-bronchodilator FEV(1)/FVC <0.70 but > or =0.70 post-bronchodilator were considered to have reversible obstruction. Bronchodilator responsiveness after albuterol 200microg was assessed using three definitions: a) FVC and/or FEV(1) increment > or =12% plus > or =200mL over baseline; b) FEV(1)> or =15% increase over baseline; and c) FEV(1) increase > or =10% of predicted value.
RESULTS: There were 756 healthy respiratory subjects, 481 subjects with reversible obstruction and 759 COPD subjects. Depending on the criterion used the proportion of person with acute bronchodilator responsiveness ranged between 15.0-28.2% in COPD, 11.4-21.6% in reversible obstructed and 2.7-7.2% in respiratory healthy. FEV(1) changes were lower (110.6+/-7.40 vs. 164.7+/-11.8mL) and FVC higher (146.5+/-14.2mL vs. -131.0+/-19.6mL) in COPD subjects compared with reversible obstructed. Substantial overlap in FEV(1) and FVC changes was observed among the groups. Acute bronchodilator responsiveness in COPD persons was associated with less obstruction and never smoking.
CONCLUSIONS: Over two-thirds of persons with COPD did not demonstrate acute bronchodilator responsiveness. The overall response was small and less than that considered as significant by ATS criteria. The overlap in FEV(1) and FVC changes after bronchodilator among the groups makes it difficult to determine a threshold for separating them. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19818867     DOI: 10.1016/j.pupt.2009.09.005

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  4 in total

1.  Modest genetic influence on bronchodilator response: a study in healthy twins.

Authors:  David Laszlo Tarnoki; Emanuela Medda; Adam Domonkos Tarnoki; Andras Bikov; Zsofia Lazar; Corrado Fagnani; Maria Antonietta Stazi; Kinga Karlinger; Zsolt Garami; Viktor Berczi; Ildiko Horvath
Journal:  Croat Med J       Date:  2015-04       Impact factor: 1.351

2.  Pre- and post-bronchodilator airway obstruction are associated with similar clinical characteristics but different prognosis - report from a population-based study.

Authors:  Sami Sawalha; Linnea Hedman; Eva Rönmark; Bo Lundbäck; Anne Lindberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-04-24

3.  The Effectiveness of Traditional Chinese Medicine (TCM) as an Adjunct Treatment on Stable COPD Patients: A Systematic Review and Meta-Analysis.

Authors:  K H Chan; Y Y S Tsoi; M McCall
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-04       Impact factor: 2.629

4.  Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility.

Authors:  Steven Pascoe; Wei Wu; Chang-Qing Zhu; Dave Singh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.